Fusion Antibodies PLC
LSE:FAB
Intrinsic Value
Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. [ Read More ]
The intrinsic value of one
FAB
stock under the Base Case scenario is
10.15
GBX.
Compared to the current market price of 3.75 GBX,
Fusion Antibodies PLC
is
Undervalued by 63%.
FAB's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
FAB or that its price is influenced by factors unrelated to fundamentals.
Fusion Antibodies PLC's market capitalization is 3.6m GBX.
FAB stock price is 3.75 GBX.
FAB stock price (3.75 GBX) is 63% less than its Intrinsic Value (10.15 GBX).
FAB. Open DCF Valuation
FAB.
FAB's Revenue has dropped by 63% over the past 12 months.
FAB's ROE (Return on Equity) has significantly decreased in the last 3 years from -61% to -141%, and is approaching profitability.
FAB's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -96% to -206%, and is approaching profitability.
FAB has negative Gross Profit for the last twelve months.
FAB has negative Operating Income for the last twelve months.
FAB has negative Net Income for the last twelve months.
FAB's ROE (Return on Equity) for the past 12 months is negative and is equal to -141%.
FAB's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -206%.
FAB's Revenue has been falling by 27% per year for the last 3 years.
FAB has negative Free Cash Flow for the last twelve months.
FAB's short-term assets (2m GBP) exceed its short-term liabilties (554k GBP).
FAB's long-term assets (2m GBP) exceed its long-term liabilties (604k GBP).
FAB's D/E (Debt to Equity) is very low and is equal to 0.02.
FAB has negative three-year average ROE (Return on Equity): -65%. The company is not efficient at transforming stockholders' equity into net income.
FAB has negative three-year average ROIC (Return on Invested Capital): -105%. The company is not efficient at using invested capital to generate operating income.
FAB has negative Net Debt. This means that the company has more cash and short-term investments (487k GBP) than debt (30k GBP).
FAB's Altman Z-Score is very low and is equal to -4.48.
Valuation Backtest
Fusion Antibodies PLC
Run backtest to discover the historical profit from buying and selling
FAB
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Fusion Antibodies PLC
Balance Sheet Decomposition
Fusion Antibodies PLC
| Current Assets | 1.8m |
| Cash & Short-Term Investments | 487k |
| Receivables | 797k |
| Other Current Assets | 524k |
| Non-Current Assets | 250k |
| PP&E | 250k |
| Current Liabilities | 554k |
| Accounts Payable | 537k |
| Other Current Liabilities | 17k |
| Non-Current Liabilities | 50k |
| Long-Term Debt | 30k |
| Other Non-Current Liabilities | 20k |
Earnings Waterfall
Fusion Antibodies PLC
|
Revenue
|
1.6m
GBP
|
|
Cost of Revenue
|
-1.7m
GBP
|
|
Gross Profit
|
-117k
GBP
|
|
Operating Expenses
|
-2.9m
GBP
|
|
Operating Income
|
-3m
GBP
|
|
Other Expenses
|
184k
GBP
|
|
Net Income
|
-2.8m
GBP
|
Free Cash Flow Analysis
Fusion Antibodies PLC
FAB Profitability Score
Profitability Due Diligence
Fusion Antibodies PLC's profitability score is 11/100. The higher the profitability score, the more profitable the company is.
Score
Fusion Antibodies PLC's profitability score is 11/100. The higher the profitability score, the more profitable the company is.
FAB Solvency Score
Solvency Due Diligence
Fusion Antibodies PLC's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Fusion Antibodies PLC's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FAB Price Targets Summary
Fusion Antibodies PLC
Shareholder Return
FAB Price
Fusion Antibodies PLC
| Average Annual Return | -0.85% |
| Standard Deviation of Annual Returns | 48.5% |
| Max Drawdown | -98% |
| Market Capitalization | 3.6m GBX |
| Shares Outstanding | 95 365 600 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Fusion Antibodies PLC
Country
Industry
Market Cap
Dividend Yield
Description
Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.
Contact
IPO
Employees
Officers
The intrinsic value of one
FAB
stock under the Base Case scenario is
10.15
GBX.
Compared to the current market price of 3.75 GBX,
Fusion Antibodies PLC
is
Undervalued by 63%.
You don't have any saved screeners yet
